Navigation Links
Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Date:5/29/2009

KRX-0401 Demonstrates Impressive Single Agent Efficacy in Patients who Progressed after Failing Treatment Either with a VEGF Receptor Inhibitor or after Treatment with both a VEGF Receptor Inhibitor and an mTOR Inhibitor

NEW YORK, May 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced data on the clinical activity of KRX-0401 (perifosine), the Company's Akt-inhibitor for cancer, as a treatment for advanced renal cell carcinoma. Abstract #5034, entitled, "Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor," was presented earlier today in a poster session at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Orlando, Florida. Later this afternoon, the data will also be presented by Dr. Brian Rini, Associate Professor of Medicine at the Cleveland Clinic Taussig Cancer Institute, in a poster discussion during the Genitourinary Cancer session.

The study enrolled a total of 50 patients, of which 46 patients were evaluable for response. Evaluable patients were defined as those who had greater than 7 days of treatment. The primary endpoint of this study was clinical benefit, defined as response rate (RECIST), and progression-free survival (PFS) in RCC patients who failed a prior VEGF receptor inhibitor (sunitinib or sorafenib). Safety of perifosine in this patient population was evaluated as a secondary endpoint. Best response to single agent perifosine was as follows: 

      Group     N       PR      SD > 12 wks    CBR*       Median PFS
                       N (%)       N (%)       N (%)       (SD or >)
     All Pts    46    5 (11%)    16 (35%)    21 (46%)      33 weeks
                                                      [95% CI (24, 
'/>"/>
SOURCE  Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
2. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
3. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
5. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
6. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
7. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
8. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
9. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
10. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
11. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Calif. , May 20, 2013 A ... for use both in space and on Earth was ... The technology assures high quality, secure ... and low-power ultrasound units, like those used in hospitals ... already the diagnostic imaging solution of choice for human ...
(Date:5/20/2013)... 20, 2013 Hyland Software expands upon ... creating the Multi-Disciplinary Clinical Leadership Team. Led by ... experts with diverse healthcare experience, the team will ... create new software solutions that will enhance the ... patients and staff. Healthcare organizations use ...
(Date:5/20/2013)...  Neuralstem, Inc. (NYSE MKT: CUR) today reported that ... investigator, presented updated Phase I data from its spinal ... treatment of amyotrophic lateral sclerosis (ALS or ... special medical symposium in Bucharest, Romania ... Advances in Stem Cell Therapy," Dr. Feldman outlined the ...
Breaking Medicine Technology:Wyle Aided System Gets Named to Space Technology Hall of Fame 2Wyle Aided System Gets Named to Space Technology Hall of Fame 3Hyland Software Forms Multi-Disciplinary Clinical Leadership Team to Augment Healthcare Solutions 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4
... N.J. and URBANA, Ill., Dec. 6, 2011  Bayer ... into an outcomes-based contract for people with relapsing-remitting ... beta-1b) to reduce the frequency of clinical exacerbations.  ... for Bayer HealthCare in the U.S. and is ...
... SPRING, Md., Dec. 6, 2011 The U.S. Food and ... issued seven Warning Letters to companies marketing over-the counter ... weight loss. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... hormone produced by the human placenta and found in ...
Cached Medicine Technology:Bayer HealthCare and Health Alliance Medical Plans Enter Outcomes-based Agreement 2Bayer HealthCare and Health Alliance Medical Plans Enter Outcomes-based Agreement 3Bayer HealthCare and Health Alliance Medical Plans Enter Outcomes-based Agreement 4FDA, FTC Act to Remove "Homeopathic" HCG Weight Loss Products from the Market 2FDA, FTC Act to Remove "Homeopathic" HCG Weight Loss Products from the Market 3
(Date:5/20/2013)... 2013 Heritage Woods of Gurnee ... County, Illinois, is hosting Breakfast and Bingo at 8:30 ... is located at 3775 Grand Ave. in Gurnee, Illinois, ... Medicaid, who need some help to maintain their independence. ... games of bingo," says Tammy Temaner-Rosas, Director of Marketing ...
(Date:5/20/2013)... Los Angeles, California (PRWEB) May 20, 2013 ... surgery done, it's not always to become ... to a May 7, 2013 ABC News report ... About Family”abcnews.go.com/Politics/OTUS/chris-christie-secretly-lap-band-weight-loss-surgery/story?id=19124435#.UZrR0bWUTDk) made it clear that the surgery ... a presidential candidate or gain celebrity status as ...
(Date:5/20/2013)... May 20, 2013 In order to prepare ... and wellness team from DrSmartphoneMD launched an article series to ... , The series launched with the precautions that ... of the DrSmartphoneMD program are not one of the 3.5 ... that more than 90% of all skin cancer cases are ...
(Date:5/20/2013)... People are so busy these days, running ... through the roof and are contributing to a number of ... mean the difference between life and death. Speakers at the ... May will share valuable, practical tools people can use to ... around them for social good. , Organised by V ...
(Date:5/20/2013)... 20, 2013 The Environmental ... feature dozens of continuing education credit opportunities for ... Institute of Architects Continuing Education System (AIA/CES), the ... the Interior Design Continuing Education Council (IDCEC). ... 1, 2013 at the Omni Providence Hotel in ...
Breaking Medicine News(10 mins):Health News:Heritage Woods of Gurnee Affordable Assisted Living Community to Host Breakfast and Bingo 2Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 2Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 3Health News:Combat Skin Cancer In Summer Months 2Health News:Chill Out and Change the World, Say Mind Experts at V Star Bliss Event in Sydney 2Health News:Environmental Design Research Conference to Feature AIA/CES, LA CES, and IDCEC Continuing Education Credits 2
... Re-elect Directors, Ratify E&Y and Approve Charter Amendment; ... Board Re-appoints Leadership, ... the "Company") said today that its Board of Directors declared,a regular ... 2008 to stockholders of record on June 4, 2008. The dividend ...
... Calif., May 19 Alexza,Pharmaceuticals, Inc. (Nasdaq: ... S.,Williams has rejoined the company in a ... a wholly owned subsidiary of Alexza. Mr.,Williams ... Alexza,subsidiary in Singapore and establishing potential joint ...
... VALLEY FORGE, Pa., May 19 The St. Jude ... first drywall ever manufactured at the,new CertainTeed Gypsum Plant ... for St. Jude Children,s Research Hospital, CertainTeed is,donating gypsum ... the,house., (Logo: http://www.newscom.com/cgi-bin/prnh/20070102/CLTU053LOGO ), The ...
... Provides Development Expertise for Partners ... Developing on the Google Health Platform, PORTLAND, Ore., May ... and development company, announced,collaboration today with Google as a development ... to the public at an,event at Google,s headquarters today; the ...
... Program seeks to advance knowledge of mysterious conditions , , ... program designed to help patients with mysterious health conditions ... U.S. National Institutes of Health. , The Undiagnosed Diseases ... to the NIH Clinical Center by doctors across the ...
... of Nebraska Medical Center-led pilot study that showed antidepressants ... and neck cancer patients is the focus of an ... one of the publications produced by the Journal of ... led by UNMCs William Lydiatt, M.D., and Bill Burke, ...
Cached Medicine News:Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 2Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 3Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 4Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 5Health News:Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd. 2Health News:Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd. 3Health News:Gypsum Wallboard from CertainTeed's Moundsville, W. Va., Plant and Roofing Shingles among Building Materials Donated to St. Jude Dream Home(R) 2Health News:Mount Tabor Collaborates with Google Health 2Health News:U.S. Turns Spotlight on Medicine's Most Puzzling Cases 2Health News:JAMA publication features study on depression and head and neck cancer 2
Adjustable wire speculum with 17 mm open blades. Lid tension adjustable throughout procedure with thumb screw control. Shaft angled 45 degrees. Manufactured in titanium....
Open 14 mm blades with 10 mm lifting wings. Lightweight wire. Dull finish....
Angled for temporal approach. Solid 14 mm blades. Dull finish....
Open 14 mm blades with 6 mm lifting wings. Dull finish....
Medicine Products: